Abstract
In the open-label, non-inferiority trial by Vijay Patil and colleagues,1 metronomic therapy was found to be non-inferior and possibly superior (pre-specified) to platinum monotherapy. Three main benefits were seen with metronomic therapy: non-inferiority of overall survival, less toxicity, and better quality of life. However, all three benefits appear less than modest on critical analysis.
Highlights
In the open-label, non-inferiority trial by Vijay Patil and colleagues,[1] metronomic therapy was found to be non-inferior and possibly superior to platinum monotherapy
Three main benefits were seen with metronomic therapy: non-inferiority of overall survival, less toxicity, and better quality of life
No standard definition of platinum resistance in head and neck cancer exists; retrospective data suggest that a similar definition is clinically useful
Summary
In the open-label, non-inferiority trial by Vijay Patil and colleagues,[1] metronomic therapy was found to be non-inferior and possibly superior (pre-specified) to platinum monotherapy. Oral metronomic therapy in head and neck cancer Three main benefits were seen with metronomic therapy: non-inferiority of overall survival, less toxicity, and better quality of life.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
